Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Saved in:
| Title: | Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. |
|---|---|
| Authors: | Heier JS; Ophthalmic Consultants of Boston, Boston, MA, USA., Lad EM; Department of Ophthalmology, Duke University Medical Center, Durham, NC, USA., Holz FG; Department of Ophthalmology, University of Bonn, Bonn, Germany., Rosenfeld PJ; Department of Ophthalmology, University of Miami, Miami, FL, USA., Guymer RH; Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia., Boyer D; Retina Vitreous Associates Medical Group, Los Angeles, CA, USA., Grossi F; Apellis Pharmaceuticals, Waltham, MA, USA., Baumal CR; Apellis Pharmaceuticals, Waltham, MA, USA., Korobelnik JF; Service d'Ophtalmologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Ophthalmology Department, University of Bordeaux, Bordeaux, France., Slakter JS; Department of Ophthalmology, New York University, New York, NY, USA., Waheed NK; New England Eye Center, Boston, MA, USA., Metlapally R; Apellis Pharmaceuticals, Waltham, MA, USA., Pearce I; Department of Ophthalmology, Royal Liverpool University Hospital, Liverpool, UK., Steinle N; California Retina Consultants, Santa Barbara, CA, USA., Francone AA; Charles Centro Oftalmológico, Buenos Aires, Argentina., Hu A; Cumberland Valley Retina Consultants, Hagerstown, MD, USA., Lally DR; New England Retina Consultants, Springfield, MA, USA., Deschatelets P; Apellis Pharmaceuticals, Waltham, MA, USA., Francois C; Apellis Pharmaceuticals, Waltham, MA, USA., Bliss C; Apellis Pharmaceuticals, Waltham, MA, USA., Staurenghi G; Department of Biomedical and Clinical Science, Ospedale Luigi Sacco University of Milan, Milan, Italy., Monés J; Institut de la Màcula, Centro Médico Teknon, Barcelona, Spain; Barcelona Macula Foundation: Research for Vision, Barcelona, Spain., Singh RP; Center for Ophthalmic Bioinformatics, Cleveland Clinic, Cleveland, OH, USA., Ribeiro R; Apellis Pharmaceuticals, Waltham, MA, USA., Wykoff CC; Retina Consultants of Texas, Houston, TX, USA; Blanton Eye Institute, Houston, TX, USA; Houston Methodist Hospital, Houston, TX, USA. Electronic address: charleswykoff@gmail.com. |
| Corporate Authors: | OAKS and DERBY study investigators |
| Source: | Lancet (London, England) [Lancet] 2023 Oct 21; Vol. 402 (10411), pp. 1434-1448. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
